More IDO Issues: NewLink Drops Pancreatic Cancer Indication For Indoximod

NewLink has scrapped plans to explore its IDO inhibitor in pancreatic cancer – more bad news for a drug class that has suffered several setbacks recently.

Juggling — NewLink juggles too many indoximod options; drops pancreatic cancer program • Source: Shutterstock

NewLink Genetics Corp. has “deprioritized” pancreatic cancer and will not proceed with a planned Phase II study testing its lead product indoximod with AstraZeneca PLC's Imfinzi (durvalumab), the company said during its first-quarter earnings announcement.

This follows on from news last month that NewLink had halted the Phase III Indigo301 study of indoximod in combination...